Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy.
We treated two diabetic patients with corneal epithelial disorder that resisted conventional medical therapy with topical CT-112 (5-[3-ethoxy-4-pentyloxyphenyl]-2,4-thiazolidinedione), a newly synthesized aldose reductase inhibitor. One patient had developed recurrent corneal erosion after vitrectomy and the other had spontaneously developed superficial punctate keratopathy. The corneal lesion in each patient responded to topical CT-112 in two to four weeks and was almost cleared within two months. A similar corneal lesion recurred in both patients soon after CT-112 was discontinued, but it disappeared again when the drug was resumed.
D000368:Aged; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D048909:Diabetes Complications; D004848:Epithelium / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D012008:Recurrence; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D009883:Ophthalmic Solutions; D013844:Thiazoles; D045162:Thiazolidinediones; C051003:risarestat; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase